FOCAL SEGMENTAL GLOMERULOSCLEROSIS

This study tests an experimental drug called sparsentan in 67 children with certain kidney diseases that cause protein leakage in urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants take the drug once daily as a liquid or tablet, and r…

This study tests a drug called sparsentan in 20 adults who have protein in their urine after a kidney transplant due to IgA nephropathy or FSGS. Participants take one pill daily for 36 weeks to see if it safely lowers protein levels and protects kidney function. The goal is to co…

This study tests whether the diabetes drug metformin can protect kidney cells in people with Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. About 30 adults will take either extended-release metformin or a placebo for 6 months, alongside their usual treatments. …

This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) in people aged 16 to 75 with two rare kidney diseases, FSGS or MCD. The goal is to see if these drugs can reduce protein in the urine, a sign of kidney damage, and help achieve remission. Partic…

This study tests a noninvasive device that gently stimulates a nerve in the ear to help children with steroid-resistant nephrotic syndrome, a kidney condition that doesn't respond to standard steroids. The goal is to see if this approach is safe, tolerable, and can reduce inflamm…

This study tests a new daily pill (BI 764198) for people with a rare kidney disease called FSGS. About 286 adults and teens will take either the study drug or a placebo for up to 2 years, while continuing their usual treatments. The goal is to see if the drug reduces protein in t…

This study tests a new drug, praliciguat, for people with a kidney disease called focal segmental glomerulosclerosis (FSGS). About 60 adults will be randomly assigned to take either the drug or a placebo for 24 weeks, followed by 24 weeks where everyone gets the drug. The main go…

This small pilot study is testing whether a gentle, non-invasive nerve stimulation device worn on the ear can help children with a frequently relapsing kidney disease. The goal is to see if this approach can reduce disease flare-ups and the need for strong steroid medications. Re…

This study is testing whether an oral powder called ManNAc can help people with FSGS, a disease that causes kidney scarring. Thirty adults with FSGS will take the powder dissolved in water twice daily for 14 weeks. Researchers will check if it safely reduces protein in the urine,…

This study gathers information and biological samples from 300 people with FSGS or MCD who have had or will have a kidney transplant. Researchers want to learn why these kidney diseases sometimes come back after transplant and how to improve treatment. Participants provide data o…

This study helps people with nephrotic syndrome and related kidney diseases find clinical trials that may be a good fit for their specific condition. Researchers use detailed molecular information from each participant to recommend targeted therapies being tested in other studies…